Longer follow-up studies are needed to inform clinical guidelines (Dunselman et al., 2014)
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021
and brought to you by Orio Pharma, stands as a revolutionary advancement in the treatment of Type 2 diabetes
Want to read about more experiences
What they found (summary): MC1R: melanogenesis, pigmentation, anti-inflammation MC2R: ACTH receptor in the adrenals (Melanotan II does not act) MC3R: energy, cardiovascular function, anti-inflammation MC4R: appetite (central control), sexual function, autonomic regulation MC5R: exocrine glands (sebaceous, lacrimal, salivary) Mutations in MC4R are the most common monogenic cause of obesity in humans Why it matters: Cones review article is the reference article for all of melanocortin pharmacology
Pipeline outlook for oral GLP-1 drugs